

## Type 2 Diabetes in adults (medicines update) Committee meeting 1

**Date:** 10/01/2023

**Location:** NICE London office/Virtual

**NICE** National Institute for  
Health and Care Excellence

**Minutes:** Final

<b>Committee members present:</b>	
Chirag Bakhai	(Present for notes 1 – 6)
Mimi Chen	(Present for notes 1 – 6)
Sithembile Thokozile Chinaire	(Present for notes 1 – 6)
Dan Cuthbertson (Topic Adviser)	(Present for notes 1 – 6)
Anne Dornhorst	(Present for notes 1 – 6)
Natasha Jaques	(Present for notes 1 – 6)
Simon Mackenzie (Chair)	(Present for notes 1 – 6)
Sharon McCarthy	(Present for notes 1 – 6)
Soon Song	(Present for notes 1 – 6)
Annette Swinkels	(Present for notes 1 – 6)

<b>In attendance:</b>		
Serena Carville	Associate Director/Guideline Lead	(Present for notes 1 – 6)
Amy Crisp	Senior Project Manager	(Present for notes 1 – 6)
Rupert Franklin	Senior Guideline Commissioning Manager	(Present for notes 1 – 6)
Sarah Glover	Information Specialist	(Present for notes 4 – 6)
Nancy Pursey	Trainee Technical Analyst	(Present for notes 1 – 6)
Muksitur Rahman	Health Economist	(Present for notes 1 – 6)
Joseph Runicles	Information Specialist	(Present for notes 1 – 6)
Meena Tafazzoli	Technical Analyst	(Present for notes 1 – 6)
David Wonderling	Head of Health	(Present for notes 1 – 6)

	Economics	
George Wood	Technical Analyst	(Present for notes 1 – 6)

**Apologies:**

Neel Basudev	Committee member
Hugh Gallagher	Committee member
Sallianne Kavanagh	Committee member
Gosia Wamil	Committee member

**1. Welcome and objectives for the meeting**

The Chair welcomed the Committee members and attendees to the first meeting on Type 2 Diabetes in adults (medicines update). The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

**2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initial and subsequent treatment of type 2 diabetes.

The Chair asked everyone to verbally declare any interests, these are noted below:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Mimi Chen	Committee member, Consultant Diabetologist	Speakers to deliver Medical Postgraduates Educations Sessions – for GPs, Hospitals specialists and community teams funded by industries. Within the last 12 months, the industries sponsors	Direct financial	Declare and participate

		included Astra Zeneca, Novartis, Boehringer Ingelheim and Novo Nordisk.		
Mimi Chen	Committee member, Consultant Diabetologist	Have secured grant for patient improvement from Industry (Novo Nordisk) for appointment of a Clinical Specialist Nurse – fund and contract with the Trust	Direct financial	Declare and participate
Mimi Chen	Committee member, Consultant Diabetologist	Have received sponsorship to attend diabetes conferences and educational events from industries, Novo Nordisk.	Direct financial	Declare and participate
Mimi Chen	Committee member, Consultant Diabetologist	Conducting industry sponsored clinical trials by Abbot, Novo Nordisk within Clinical Research Facility at the Trust – funding goes to hospital central fund	Direct financial	Declare and participate
		Private practice in management of diabetes patients		
Mimi Chen	Committee member,	Principal investigator	Direct, non-	Declare and

	Consultant Diabetologist	for diabetes research sponsored by industries at my current hospital	financial	participate
Dan Cuthbertson	Topic Adviser, Consultant Diabetologist	Conference attendance at ADA: Perspectum (Imaging company)	Direct, financial	Declare and participate
Dan Cuthbertson	Topic Adviser, Consultant Diabetologist	Speaker fees (paid to University of Liverpool) for Astra Zeneca/Novo Nordisk	Direct, financial	Declare and participate
Dan Cuthbertson	Topic Adviser, Consultant Diabetologist	Investigator-initiated research proposals funded by BMS, Novo Nordisk and Astra Zeneca	Direct, financial	Declare and participate
Dan Cuthbertson	Topic Adviser, Consultant Diabetologist	Limited private practice (10-20 Endocrinology patients seen per year)	Direct, financial	Declare and participate
Natasha Jaques	Committee member, Pharmacist	Member of UKCPA Diabetes and Endocrinology committee	Direct, financial	Declare and participate
Natasha Jaques	Committee member, Pharmacist	Speaker at Diabetes Professional Care Conference	Direct, non-financial.	Declare and participate
Simon Mackenzie	Chair, retired medical director	Member of Medical Practitioner Tribunal	Direct, financial	Declare and participate

		Service committee.		
<p>The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.</p>				
<p><b>3. Presentations</b></p>				
<p>The Chair introduced GW who gave a short introductory presentation on the guideline review process.</p> <p>GW took questions from the group.</p> <p>The Committee thanked GW for their presentation and contribution to the development of the guideline.</p>				
<p><b>4. Protocols</b></p>				
<p>GW presented the following draft protocol to the committee:</p> <ul style="list-style-type: none"> <li>• 1.1 Initial treatment</li> </ul> <p>The Committee discussed the protocol and were given the opportunity to ask questions.</p>				
<p><b>5. Health Economics</b></p>				
<p>The Chair introduced MR who gave a presentation on the health economics of this guideline update.</p> <p>MR took questions from the group.</p> <p>The Committee thanked MR for their presentation and contribution to the development of the guideline.</p>				
<p><b>6. AOB</b></p> <p>None.</p>				

**Date of next meeting:** 08/03/2023

**Location of next meeting:** Virtual